glp-1 peptide Crystal structure of the receptor bound to a agonist Structure-Based Discovery of Orthosteric Non-Peptide

Lotiglipron The development of lotiglipron for obesity and T2DM was prematurely stopped in early-phase clinical trials due to its association with elevated transaminases and potential liver toxicity

Avoid the same foods you avoided on medication since the reasons for avoiding them, rapid glucose spikes, low satiety, gastrointestinal distress, remain relevant even without the medication

As previously reported, women with a history of PE are at an increased risk of long-term coronary heart disease, heart failure, stroke, and cardiovascular disease-related death later in life 3 , and their offspring are also at an elevated risk of hypertension and cardiovascular disease 4

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS